UCB Announces Plan to Seek Regulatory Approval for Fintepla in CDKL5 Deficiency Disorder Following Positive Phase 3 Results
UCB announced that it will move forward with regulatory submissions for Fintepla® (fenfluramine) as a treatment for seizures associated with […]